Tamiflu News and Research

RSS

Taiwan scientists confirm world’s first case of wild avian influenza A H6N1 virus in human

Scientists from Taiwan report on the world’s first confirmed case of human infection with a wild avian influenza A H6N1 virus in The Lancet Respiratory Medicine.

14 Nov 2013

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

NanoViricides, Inc. announced today that the European Medicines Agency, has awarded orphan drug designation to DengueCide, the Company's drug candidate for the treatment of dengue and dengue hemorrhagic fever.

11 Nov 2013

Bioactive compounds in carrot can be used as antiviral for treatment against flu

Researchers from the FEMSA Center of Biotechnology at Technologic of Monterrey (ITESM) designed a technology that uses grated carrot to obtain phenolic compounds that have a potential to prevent cancer, and cardiovascular and neurodegenerative diseases.

5 Oct 2013

Scientists identify chemical agents that block flu virus's ability to replicate itself in cell culture

A new way to attack flu viruses is taking shape in laboratories at Rutgers University, where scientists have identified chemical agents that block the virus's ability to replicate itself in cell culture.

4 Oct 2013

Kentucky researcher uses advanced biomedical technology to study HMPV

You may not know the human metapneumovirus by name, but chances are that you have met somewhere before.

22 Aug 2013

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

NanoViricides, Inc. said it has signed a non-disclosure agreement with the Lovelace Respiratory Research Institute. The Company intends to enter into a Master Services Agreement with LRRI for the IND-enabling efficacy studies of both its broad-spectrum injectable and oral FluCide drug candidates.

5 Aug 2013

Some strains of avian H7N9 influenza develop resistance to antiviral drugs

Some strains of the avian H7N9 influenza that emerged in China this year have developed resistance to the only antiviral drugs available to treat the infection, but testing for antiviral resistance can give misleading results, helping hasten the spread of resistant strains.

17 Jul 2013

New paper analytical devices can screen fake antimalarial drugs

On Wednesday, 5/29/13, the Wall Street Journal published an article titled "Africa's Malaria Battle: Fake Drug Pipeline Undercuts Progress." The piece outlines a counterfeit pharmaceutical problem that is top of mind at Saint Mary's College in Notre Dame, IN. Chemistry Professor Toni Barstis and her undergraduate students at this Catholic, women's, liberal arts college have researched and developed Paper Analytical Devices (PADs) that can screen whether an antimalarial drug is real.

1 Jun 2013

Romark Laboratories starts NT-300 Phase 3 trial for treatment of acute uncomplicated influenza

Romark Laboratories announced that it has begun enrolling patients in a global Phase 3 clinical trial of NT-300 (nitazoxanide) for treatment of acute uncomplicated influenza.

19 Apr 2013

New assays are effective in managing patients with influenza virus infection

Over 40,000 people die each year in the United States from influenza-related diseases. In patients whose immune systems are compromised, antiviral therapy may be life-saving, but it needs to be initiated quickly. It is therefore crucial to diagnose and type the influenza rapidly.

18 Apr 2013

Study: Half of Tamiflu prescriptions during 2009-10 influenza pandemic went unused in England

A new study concludes that approximately half of the prescriptions of Tamiflu during the 2009-10 influenza pandemic went unused in England.

18 Apr 2013

Reports of H7N9 cases, deaths continue from across China

"Two more people have died in China from a new strain of bird flu, raising the death toll from the virus to 13, state media reported Sunday," the Associated Press reports.

16 Apr 2013

Influenza drug: an interview with Dr Jenny McKimm-Breschkin, CSIRO

Influenza or flu for short is caused by a family of viruses, which can be called influenza A or influenza B. Influenza A viruses are found in humans, animals – like swine and horses- and mostly aquatic birds. Influenza B is only found in humans.

11 Mar 2013

Researchers identify new function for matriptase enzyme

Dr. Martin Richter (pharmacology), investigator with the Centre de recherche clinique Étienne-Le Bel (CRCELB) at the Centre hospitalier universitaire de Sherbrooke (CHUS) and professor in the Faculty of Medicine and Health Sciences of the Université de Sherbrooke (UdeS), and his collaborators have identified a new function of the enzyme matriptase, present in the human respiratory system, that can activate a viral protein involved in infections caused by the H1N1 influenza (or flu) virus.

24 Feb 2013

LASAG trial for severe influenza initiated

...

12 Feb 2013

91 charged with $430 million Medicare billing fraud

The nationwide sweep involved arrests of doctors, nurses and other licensed medical professionals.

6 Oct 2012

NanoViricides’ oral FluCide dramatically improves survival in animals with H3N2 influenza A

NanoViricides, Inc. reported today that its oral FluCide drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of the H3N2 influenza A virus.

24 Sep 2012

Strong antiviral antibody response observed in oral administration of Flucide

NanoViricides, Inc. announced today that anti-influenza drug candidates under its FluCide program, when given orally, led to strong antiviral antibody response. The antibody response with Oral administration was stronger than that with IV administration and was substantially greater than that observed with oseltamivir.

5 Sep 2012

Oral FluCide drug candidates effective in reducing lung viral load: NanoViricides

NanoViricides, Inc. announced today that anti-influenza drug candidates under its FluCide program, when given orally, were nearly as effective as when administered as IV injections in terms of reduction in lung viral load.

27 Aug 2012

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

Gilead Sciences, Inc. announced today its results of operations for the quarter ended June 30, 2012.

26 Jul 2012